We request support for a Multidisciplinary Cancer Research Training Program (MCRTP) at the University of Utah. Our goal is to train pre- and postdoctoral scientists who will initiate independent careers in cancer research. Trainees will acquire a deep understanding of clinical and mechanistic aspects of cancer, highly developed technical and analytical skills, an appreciation for the value of interdisciplinary, collaborative research, and a commitment to pursuing cancer-focused studies. The training program has four key elements: 1) All trainees will engage in cancer research projects under the direct supervision of the faculty. 2) All trainees will participate in a specialized curriculum that includes two cancer-focused didactic courses, a course on scientific integrity, and regularly scheduled Journal Clubs and Tumor Boards. 3) All trainees will obtain frequent feedback from faculty through an individual advising mechanism. 4) All trainees and mentors will meet regularly to attend the Huntsman Cancer Institute Seminar Series, an Annual Retreat, and a Cancer Biology Discussion Group. A strength of the MCRTP is the collaboration of physicians and basic scientists who are interested in cancer research. The training faculty is comprised of 45 clinical- and laboratory-based investigators, all of whom have extramural funding for their research and are engaged in one or more cancer-related projects. Predoctoral trainees will be highly qualified, advanced graduate students. Postdoctoral trainees will include both M.D.s and Ph.D.s who seek focused training in cancer research. An Executive Committee will appoint trainees and will conduct regular reviews of their progress. MCRTP trainees will be integrated into a highly interactive, interdisciplinary community of researchers committed to understanding cancer biology and translating that information into more effective strategies for diagnosis and treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA093247-04
Application #
6891071
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2002-02-19
Project End
2007-01-31
Budget Start
2005-03-11
Budget End
2006-01-31
Support Year
4
Fiscal Year
2005
Total Cost
$463,875
Indirect Cost
Name
University of Utah
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Wagle, M; Eiring, A M; Wongchenko, M et al. (2016) A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia 30:1493-501
Jimenez, Laura; Wang, Jindong; Morrison, Monique A et al. (2016) Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis. Dis Model Mech 9:389-400
Piccolo, Stephen R; Hoffman, Laura M; Conner, Thomas et al. (2016) Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol 12:860
Khorashad, J S; Tantravahi, S K; Yan, D et al. (2016) Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia 30:2275-2279
Woods, Ryan D; O'Shea, Valerie L; Chu, Aurea et al. (2016) Structure and stereochemistry of the base excision repair glycosylase MutY reveal a mechanism similar to retaining glycosidases. Nucleic Acids Res 44:801-10
Khorashad, Jamshid S; Eiring, Anna M; Mason, Clinton C et al. (2015) shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood 125:1772-81
Piccolo, Stephen R; Andrulis, Irene L; Cohen, Adam L et al. (2015) Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. BMC Med Genomics 8:72
Eiring, Anna M; Page, Brent D G; Kraft, Ira L et al. (2015) Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 29:586-597
Pomicter, Anthony D; Eiring, Anna M; Senina, Anna V et al. (2015) Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol 43:537-45.e1-11
Eiring, A M; Khorashad, J S; Anderson, D J et al. (2015) ?-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 29:2328-37

Showing the most recent 10 out of 64 publications